SHANGHAI -- Shares in the main pharmaceuticals unit of Chinese conglomerate Fosun International rose sharply on Tuesday as investors applauded its role in what could be a breakthrough global COVID-19 vaccine.
Pfizer, the U.S. pharma group, and Germany's BioNTech said on Monday that their candidate mRNA vaccine BNT162b2 had demonstrated efficacy of over 90% based on an analysis of its pre-manufacturing phase 3 clinical trial, usually the last hurdle before a drug goes into production.
